Nanomedicine to advance the treatment of bacteria-induced acute lung injury. Issue 44 (21st October 2021)

• Record Type: Journal Article
• Authors: Su, Ruonan; Zhang, Yu; Zhang, Jiabin; Wang, Haixia; Luo, Yun; Chan, Hon Fai; Tao, Yu; Chen, Zhuanggui; Li, Mingqiang
• Is Part Of: Journal of materials chemistry. Volume 9:Issue 44(2021)
• Page Start: 9100
• Page End: 9115
• Publication Date: 2021-10-21
• Subjects: Materials -- Periodicals; Chemistry, Analytic -- Periodicals; Biomedical materials -- Research -- Periodicals; 543.0284
• DOI: 10.1039/d1tb01770e
• Languages: English
• ISSNs: 2050-750X

Abstract

Abstract : This review aims to highlight the recent advances, key limitations, and future directions of nanomedicine for bacteria-induced acute lung injury treatment. Abstract : Bacteria-induced acute lung injury (ALI) is associated with a high mortality rate due to the lack of an effective treatment. Patients often rely on supportive care such as low tidal volume ventilation to alleviate the symptoms. Nanomedicine has recently received much attention owing to its premium benefits of delivering drugs in a sustainable and controllable manner while minimizing the potential side effects. It can effectively improve the prognosis of bacteria-induced ALI through targeted delivery of drugs, regulation of multiple inflammatory pathways, and combating antibiotic resistance. Hence, in this review, we first discuss the pathogenesis of ALI and its potential therapeutics. In particular, the state-of-the-art nanomedicines for the treatment of bacteria-induced ALI are highlighted, including their administration routes, in vivo distribution, and clearance. Furthermore, the available bacteria-induced ALI animal models are also summarized. In the end, future perspectives of nanomedicine for ALI treatment are proposed.